Neuronetics Sponsors the 5th International Brain Stimulation Conference
Poster Session Highlights the Strong Dose-Response Relationship and the Importance of Treating Beyond 30 Treatments With NeuroStar Advanced TherapyMALVERN, Pa.,...
Brain
Ocean Biomedical to Ring The Nasdaq Stock Market Opening Bell
Ocean Biomedical commenced trading on Nasdaq under ticker symbol "OCEA" on February 15 Providence, RI and New York, NY, Feb....
Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine Award
Prestigious award presented by Society for Brain Mapping & Therapeutics (SBMT) and the World Brain Mapping FoundationPALO ALTO, Calif. and...
Trevena Announces Publication of OLINVYK Respiratory Physiology Study In ANESTHESIOLOGY
OLINVYK demonstrated a reduced impact on respiratory depression compared to IV morphine, among elderly/overweight subjects Study consistent with prior results...
Neurona Therapeutics Announces FDA Clearance of Expanded Inclusion Criteria for Phase I/II Clinical Trial of NRTX-1001 Regenerative Cell Therapy in Patients with Dominant Hemisphere Drug-Resistant Focal Epilepsy
NRTX-1001 administration is well-tolerated and shows seizure reduction of >90% in the first two patients at six- and three-months post-treatment,...
DiagnaMed Prioritizes Development and Commercialization Initiatives for CERVAI™, a Brain Health AI Platform Leveraging Generative AI
CERVAI™ to be available in May 2023TORONTO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”)...
KKR-backed Replay and MD Anderson form new product company Syena to pioneer first-in-class TCR-NK cell therapy
KKR-backed Replay and MD Anderson form new product company Syena to pioneer first-in-class TCR-NK cell therapy Cord blood-derived T-Cell Receptor...
Acasti Pharma Reports Third Quarter 2023 Operational Results
Company to Host Conference Call Today at 1:00pm ET LAVAL, Québec, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc....
Hyperfine, Inc. Announces FDA Clearance for Improved AI-Powered Software and Expanded Field of View for the Swoop® Portable MR Imaging® System
Latest Swoop® software improves image quality for DWI imaging of the brainGUILFORD, Conn., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Hyperfine,...
Cannabix Technologies to Test Contactless Alcohol Breathalyzer (CAB) in Montana
Cannabix has developed a contactless alcohol breathalyzer for employers and vehicles Cannabix Contactless Alcohol Breathalyzer Contactless Alcohol Breathalyzer for workplace...
Acer Therapeutics Announces Full Enrollment of Phase 2a Trial of ACER-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause
Topline trial results expected mid-March 2023NEWTON, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical...
Cerevance Expands Series B Financing with Additional $51 Million
Proceeds will advance Cerevance’s potential first-in-class programs developed using proprietary NETSseq platform CVN424 for Parkinson’s disease will advance to Phase...
BrainsWay Announces Appointment of Hadar Levy as CEO
BURLINGTON, Mass. and JERUSALEM, Feb. 13, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
BrainsWay Announces Appointment of Ami Boehm as New Chairman
David Zacut, M.D., Relinquishing Chairman Role Held Since Company’s Inception, to Now Serve as Board DirectorBURLINGTON, Mass. and JERUSALEM, Feb....
DiagnaMed Announces Appointment of New Director
TORONTO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED), a digital health generative...
Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural Integrity
MRI results reinforce the clinical neurological improvements previously reportedMRI results showed improved brain neuronal structural integrity, independent of an immunomodulatory...
Inside Information: Nexstim Plc’s change negotiations have been completed
Company Announcement, Helsinki, 8 February 2023 at 3 PM (EET) Inside Information: Nexstim Plc’s change negotiations have been completed Nexstim...
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Ulixacaltamide (PRAX-944) Phase 2b Essential1 study topline results for essential tremor expected in 1Q23; Praxis to enter quiet period following...
Achieve Life Sciences Announces Last Subject Dosed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation
Topline Data Expected in 2Q 2023SEATTLE, Wash and VANCOUVER, British Columbia, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences,...
Ashvattha Therapeutics Announces First Patient Enrolled in a Phase 1 Study of [18F]OP-801 for Use as Imaging Agent
– The study will evaluate the safety, tolerability and ability of OP-801 to cross the blood brain barrier and selectively...